Igixon

Desogestrel, the active ingredient in Igixon, is a combined oral contraceptive presented as an oral tablet for oral administration. Together with ethinylestradiol, it provides hormonal regulation that prevents ovulation and creates cervical mucus changes, offering reliable contraception for women of reproductive age seeking pregnancy prevention.

GNH USA supplies Igixon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable supply chains and responsive technical support.

Igixon, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.

Contraception: prevents pregnancy by inhibiting ovulation and fertilization. Menstrual cycle regulation: helps achieve more regular menstrual bleeding patterns. Acne management: may improve acne associated with androgen excess.

Igixon may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nausea - Breast tenderness - Headache - Weight gain - Mood changes - Spotting between periods

Serious or Rare Side Effects: - Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism) - Arterial thrombosis (stroke, myocardial infarction) - Severe hypertension - Liver dysfunction or cholestasis - Gallbladder disease (biliary colic, cholelithiasis) - Anaphylactic or severe allergic reaction

Before prescribing Igixon, clinicians should consider several precautionary measures to ensure safe use.

Pregnancy testing: confirm non‑pregnant status before initiating therapy. Smoking: avoid in women over 35 who smoke due to increased thrombotic risk. History of thromboembolism: assess for prior clotting disorders. Liver disease: evaluate hepatic function prior to use. Missed dose: follow specific guidance for missed tablets. Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Igixon can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampin, carbamazepine, phenytoin) may markedly reduce contraceptive efficacy. - Anticoagulants (warfarin) may have unpredictable effects on clotting parameters.

Moderate Interactions (Monitor Closely): - Antifungal agents (ketoconazole, itraconazole) can increase hormone levels, requiring monitoring. - SSRIs (fluoxetine, sertraline) may increase bleeding risk. - Herbal supplements (St. John’s wort) may lower contraceptive effectiveness.